S eason's greetings! Another year is coming to a close, and in retrospect, it has been a difficult yet productive one. Finan cially, the Society for Biomolecular Sciences (SBS) weathered the economic crisis, and we will close out the year with approxi mately 72% cash reserves. Like most organizations, we faced challenges. Because of budget cuts and travel restrictions in many companies, we experienced a 16% dip in conference attendance. This is comparable to the average 15% decrease in conference attendance reported by other scientific organizations. Having lea rned from past experience that our conference attendance drops when we go to Europe, we planned for lower attendance and added a buffer for fluctuations in the currency exchange, which helped to lessen the blow. However, in the end, our profit from the annual conference fell well below what we had budgeted, which forced us to eliminate some open positions, turn to more outsourcing, and reduce expenses in functional areas.
MEETINGS
On a more positive note, SBS continues to rank as the pre miere organization supporting drug discovery. In a recent sur vey published in Genome Technology magazine, 1000 people were asked to evaluate 44 meetings to learn which offered the best return on investment. SBS ranked third, after the Association for Biomolecular Resource Facilities and qPCR. The SBS Con ference Committee deserves credit for all its efforts in attaining this rating.
Looking back at this year's programs, the SBS 15th Annual Conference & Exhibition in Lille, France, offered numerous topics related to drug discovery, including technologies, target biology, and a special 2day symposium on Gproteincoupled receptors (GPCRs). Abstracts, posters (.pdf), and recordings from the conference can all be found at www.sbsonline.org.
In September, we partnered with 2 organizations, the Interna tional Society for Stem Cell Research and the Harvard Stem Cell Institute, to host a 2day event in Boston, Massachusetts, titled "Screening Stem Cells: From Reprogramming to Regenerative Medicine." This meeting drew more than 300 attendees and 21 exhibiting companies. The quality and depth of scientific content was extraordinary. Even more exciting, through the generosity of the Genetics Policy Institute, this meeting was videotaped for ext ended viewing online at www.sbsonline.org/stemcells.
In November, in San Diego, California, SBS held a success ful followup symposium on labelfree technology. SBS con tinues to draw on hot topics to keep our members informed of the latest in science and technology.
Looking 
EDUCATION
The Education Committee worked diligently this year to offer 3 new online courses: Enzymology in Drug Discovery, Fundamentals of ADME and Toxicology Assessment for Pre clinical Drug Discovery, and Human Primary Cells & Stem Cells in Drug Discovery Applications. In a tight economy, these virtual courses offer opportunities to learn from experts in the field without spending extended time away from work. Looking ahead, the committee is working on 4 additional courses for 2010: Target to Therapy, Introduction to Biomarkers, Ion Channels, and Introduction to Pharmacology. We are also investigating business courses that support and enhance career development-for example, we are in discussions with Harvard Business Publishing about a course that would address busi ness basics.
PUBLICATIONS
The results are in from the Institute for Scientific Information (ISI), and the impact factor for the Journal of Biomolecular Sciences (JBS) rose from 2.148 to 2.365. In June, a special issue of JBS was devoted to compound management. A special issue in 2010 will cover highcontent imaging, screening, and analy sis. The recent reader survey conducted by SAGE Publications also reported that 75% of members read SBS News thoroughly or skim each issue.
In closing, I want to wish everyone a very happy holiday season and best wishes for 2010.
